GlassScriptPhysician profile
Ashish Pramod Sheth
NPI 1487645073
$6,810.73
in general payments reported to CMS, 2019-2025
35 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $465 · 2021: $758 · 2022: $818 · 2023: $1,026 · 2024: $1,564 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,067.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.98 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $858.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $824.86 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $623.29 | 2019-2022 | |
| Pfizer INC. | $345.91 | 2019-2025 | |
| Lilly USA, LLC | $281.28 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $277.70 | 2023-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $258.17 | 2021-2025 | |
| Dexcom, INC. | $232.03 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $227.72 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $207.99 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.72 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $158.74 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.37 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $132.85 | 2023-2025 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $120.32 | 2021 | |
| Merck Sharp & Dohme LLC | $116.44 | 2019-2025 | Verquvo, Belsomra |
| Exact Sciences Corporation | $115.70 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $114.26 | 2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $74.41 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.59 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $59.82 | 2022-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $56.15 | 2022 | |
| Shield Therapeutics INC | $54.54 | 2024 | |
| Paratek Pharmaceuticals, INC. | $47.40 | 2020-2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $40.73 | 2019-2021 | |
| Nevro Corp. | $32.60 | 2022 | |
| Abbott Laboratories | $31.20 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $30.99 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $29.04 | 2020-2021 | |
| Allergan, INC. | $27.23 | 2020 | |
| Apria Healthcare LLC | $26.56 | 2021 | |
| Viatris Specialty LLC | $19.69 | 2025 | Yupelri |
| Medtronic, INC. | $16.78 | 2025 | Minimed 780g |
| Cequr Corporation | $6.67 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.